Navigation Links
OPKO Health, Inc. Invests in ChromaDex® Corp.
Date:2/16/2012

MIAMI & IRVINE, Calif., Feb. 16, 2012 /PRNewswire/ -- OPKO Health, Inc. and ChromaDex Corporation (OTCBB: CDXC) announced today they have entered into a strategic alliance pursuant to which ChromaDex has licensed to OPKO all of its new product offerings and health care technologies for distribution and business development throughout all of Latin America. The initial products to be commercialized are BluScience™ (www.bluscience.com), ChromaDex's recently launched line of dietary supplements, as well as ChromaDex's proprietary pterostilbene, branded as pTeroPure® (www.pteropure.com). OPKO recently made a $1,000,000 investment in ChromaDex as a participant in a private placement of 4,993,329 shares of ChromaDex common stock.

(Logo:  http://photos.prnewswire.com/prnh/20110830/LA59283LOGO)

Dr. Phillip Frost, OPKO's Chairman and Chief Executive Officer, commented, "This new agreement with ChromaDex will utilize OPKO's extensive marketing and sales experience in Latin America to commercialize ChromaDex's products and technologies throughout the region. We are enthusiastic about pTeroPure®, one of the most promising natural ingredients to be introduced in some time, as it will help with OPKO's strategy of introducing interesting new products in rapidly growing markets."

Commenting on the announcement, Jeffrey Himmel, CEO of ChromaDex stated, "Partnering with OPKO provides a unique opportunity for ChromaDex. OPKO's resources and capabilities in Latin America make it an ideal partner. We see Latin America as a bright spot with great long-term economic prospects. The alliance with OPKO is the perfect platform to exploit our new product offerings and healthcare technologies."

ChromaDex recently launched BluScience™ (www.bluscience.com), an innovative line of dietary supplements. The novel ingredient in BluScience™ is pterostilbene, branded as pTeroPure® (www.pteropure.com), named the 2010 North American Most Promising Ingredient of the Year by the independent research company, Frost & Sullivan. pTeroPure® is a proprietary, nature-identical formulation of the antioxidant compound pterostilbene, found naturally in blueberries. Pterostilbene has superior biological activity, better oral bioavailability and is metabolized more slowly in the body than other polyphenols (antioxidant phytochemicals that tend to prevent or neutralize the damaging effects of free radicals), allowing more time for its antioxidant activities to act. Pterostilbene has shown promise for supporting cardiovascular health, cognitive function and anti-aging*. However, the amount of pterostilbene present in a typical serving of blueberries is a tiny fraction of the amount needed to realize its benefits.

About OPKO Health:

OPKO is a multi-national biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large and rapidly growing medical markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.

About ChromaDex®:

ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an expanding pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights pending. The company recently launched its BluScience™ line of dietary supplements, now available at Drugstore.com. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure for the skincare and pharmaceutical markets, among others. pTeroPure is currently being studied in a human clinical trial at the University of Mississippi.

For more information about pTeroPure visit www.pteropure.com or call 949-600-9694.

Forward-Looking Statements:

Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding the anticipated benefits, biological activity and opportunities and promise related to ChromaDex's suite of products and technologies, including pTeroPure®. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Contacts

OPKO Health, Inc. Contact:
Steve Rubin, 305-575-6015
or
ChromaDex Investor Contact:
Liviakis Financial Communications, Inc.
John M. Liviakis, 415-389-4670
President
John@Liviakis.com 
or
Institutions and Analysts Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, 858-794-9500
President
bprag@delmarconsulting.com 
or
ChromaDex / BluScience Contact:
Jeffrey Himmel, 949-419-0288
CEO
jsh@chromadex.com


'/>"/>
SOURCE ChromaDex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Zacks Releases Four Powerful Buy Stocks: Chemtura, Cardinal Health, HiTech Pharmacal and Gardner Denver
2. Tanzania Minister of Health, on Behalf of the Government, Promises Full Support to Vantage Health in the United Republic of Tanzania
3. Aria Health, Two More Healthcare Providers Choose OnBase for ECM
4. Cardinal Health, Prime Therapeutics Renew Primary Distribution Agreement
5. Inovio Pharmaceuticals Subsidiary, VGX Animal Health, to Present at VetHealth Global 2011, June 14-17, 2011
6. Nonin Medical Announces Mark VanderWerf, Vice President-eHealth, Elected to American Telemedicine Association College of Fellows
7. Telome Health, Inc. Launches With Exclusive IP Portfolio
8. Partners In Health, Abbott and the Abbott Fund Unite to Combat Severe Childhood Malnutrition in Haiti
9. NDRI Has Been Awarded $3.59 Million From the National Institutes of Health, The Directors Common Fund to Provide Human Tissue for GTEx, the New Genotype-Tissue Expression Project
10. Anodyne Health, Seven Other Companies Join in Significant Expansion of MedAxiom Corporate Partner Program
11. Three in Ten Americans Would Use Their Cell Phone to Track Personal Health, Finds PricewaterhouseCoopers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... Nov 30, 2016 Research and Markets has ... Monitoring Devices 2017 - MedCore" report to their offering. ... , , ... the skull. In healthy individuals, it is circulated though the brain and ... where the amount of CSF surrounding the brain changes significantly. ...
(Date:11/30/2016)... Research and Markets has announced the addition of the ... their offering. ... Detachable coil embolization is a minimally invasive method ... embolization treatment of cerebral aneurysms is less invasive and requires less recovery ... wall of an artery in the brain. This area bulges in the ...
(Date:11/30/2016)... Calif. , Nov. 30, 2016 Varian ... it was named America,s Most JUST Company in the ... and Forbes magazine,s inaugural "JUST 100 List." ... of the largest surveys ever conducted on attitudes towards ... months. This inaugural list ranks U.S companies against their ...
Breaking Medicine Technology:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... proudly announces the launch of its 60-day free trial program for all of ... shipping make the offer a truly hassle free experience. , FlexiSpot’s unique desktop ...
(Date:12/2/2016)... ... 02, 2016 , ... With the number of pain management programs available for ... find the one that works for them. When an inventor from Suisun City, Calif., ... and decided to share it with others. , He developed a prototype for PRO ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is proud to ... which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping ... prolonging life 6 years in the last 3 decades,” says Dr. Valentine Fuster, ...
(Date:12/2/2016)... ... , ... Sourced from the Isbre Springs beneath the 5,000 year old Hardanger ... of just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent taste ... several ShopRite and FoodTown stores in NJ and received rave comments from consumers. , ...
(Date:12/2/2016)... Francisco, CA (PRWEB) , ... December 02, 2016 ... ... digitally-enabled care journeys, announced today that it has raised $6.0 million in an ... inspired by Clarify Health’s conviction that patients and their caregivers can receive far ...
Breaking Medicine News(10 mins):